Smad1 as a Biomarker for Diabetic Nephropathy

Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway

addict submitted, created time 1 year 7 months (www.nature.com)

Endoglin is a transforming growth factor beta (TGFbeta) superfamily auxiliary receptor. We had previously shown that it suppressed prostate cancer (PCa) cell motility, and that its expression was lost during PCa progression. The mechanism by which endoglin inhibits PCa cell motility is unknown. Here we demonstrate that endoglin abrogates TGFbeta-mediated cell motility, but does not alter cell surface binding of TGFbeta.

Submit comment | Blog It | Email It | Keywords: transforming growth factor beta prostate cancer motility endoglin smad1 ALK2